A prospective, randomised, double-blinded, placebo-controlled, single ascending dose study investigating the safety and local tolerability of STA363 compared to placebo in 15 patients with chronic discogenic low back pain

Trial Profile

A prospective, randomised, double-blinded, placebo-controlled, single ascending dose study investigating the safety and local tolerability of STA363 compared to placebo in 15 patients with chronic discogenic low back pain

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2018

At a glance

  • Drugs Lactic acid (Primary)
  • Indications Back pain
  • Focus Adverse reactions; First in man
  • Sponsors Stayble Therapeutics
  • Most Recent Events

    • 11 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 31 Aug 2018 Biomarkers information updated
    • 19 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top